Phillips Medisize acquires full Chippenham site footprint for inhalation development
Company / institutional announcement · Phillips Medisize / Business Wire
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What changed
Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.
Why it may matter
Analysis: Greater operational control may strengthen outsourced inhalation development and clinical supply continuity, although projected demand is a company expectation.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections